The UK’s MHRA and Genomics England have launched a groundbreaking study to investigate whether genetics play a role in ...

Innovent Biologics, Inc. (“Innovent”) (HKEX: 01801), a world-class biopharmaceutical company that develops, man ...

The quest for weight loss has taken a dramatic turn. A wave of new-age solutions, from once-weekly injectables like Wegovy ...

Combination therapy with a long-acting amylin analogue and a glucagon-like peptide-1 (GLP-1) receptor agonist results in ...

GLP-1 receptor agonists show promise in reducing cancer risk and enhancing early detection, highlighting the need for further research in oncology.

For reference, Novo Nordisk also offers a highly successful weight loss drug, Wegovy, a GLP-1 receptor agonist.

A new expert consensus statement issued by the American College of Cardiology said that cardiologists should “embrace” new weight-loss medications for patients with obesity, TCTMD reported June 25.

Altimmune’s GLP-1/glucagon dual receptor agonist achieved a hit and a miss when it came to the dual goals of a phase 2 ...

Signs of advanced chronic pancreatitis include weight loss, a loss of appetite, jaundice, other symptoms associated with ...

GLP-1 receptor agonists may increase the risk of several autoimmune diseases in adults with type 2 diabetes, according to ...

"These drugs have the potential to change societies, not just individuals." — Michael Le Page, New Scientist, March 29, 2025 ...

People undergoing metabolic and bariatric surgery are less likely to develop psychiatric disorders than those treated with GLP-1 RAs.